1. Emgality, manufactured by Eli Lilly, is the first migraine treatment approved in the U.S. for decreasing the frequency of episodic cluster headache attacks.
2. Zerbaxa, a combination of cephalosporin ceftolozane and tazobactam, was approved for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. The drug was initially approved in 2014 to treat intra-abdominal infections and complicated urinary tract infections.
3. Slynd is a progestin-only contraceptive. It has 24 active pills and 4 inactive ones. It allows for a 24-hour missed-pill window.
4. Nexus, manufactured by Misonix, integrates the features of three previous platforms used for cutting bone, removing tumors and trimming foreign material and damaged tissue from wounds.
More articles on pharmacy:
Viewpoint: The $2.1M drug price record won’t last long
Purdue Pharma hit with 4 more opioid lawsuits: 4 things to know
EpiPen shortage will drag on: 4 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
